Tracon Pharmaceuticals, Inc. financial data

Symbol
TCON on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4350 La Jolla Village Drive, Suite 800, San Diego, California
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 62 % -35%
Return On Equity -32.7 % -105%
Return On Assets 17 %
Operating Margin -77 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.68 M shares -88.8%
Common Stock, Shares, Outstanding 2.66 M shares -88.9%
Entity Public Float 7.6 M USD -82%
Common Stock, Value, Issued 3 K USD -87.5%
Weighted Average Number of Shares Outstanding, Basic 2.39 M shares +89.9%
Weighted Average Number of Shares Outstanding, Diluted 2.39 M shares +89.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 100 K USD
Research and Development Expense 9.19 M USD -42.1%
General and Administrative Expense 5.76 M USD -41.8%
Operating Income (Loss) -5.17 M USD +79.9%
Nonoperating Income (Expense) 6.92 M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 1.75 M USD +62.7%
Earnings Per Share, Basic 5.32 USD/shares +80.3%
Earnings Per Share, Diluted 5.32 USD/shares +80.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.89 M USD +19.4%
Cash, Cash Equivalents, and Short-term Investments 8 M USD +19.4%
Assets, Current 8.4 M USD +17.7%
Property, Plant and Equipment, Net 33 K USD -29.8%
Operating Lease, Right-of-Use Asset 905 K USD -19.4%
Assets 9.36 M USD +12.4%
Accounts Payable, Current 2.68 M USD
Employee-related Liabilities, Current 414 K USD -77.5%
Accrued Liabilities, Current 7.36 M USD
Liabilities, Current 10.5 M USD -26.3%
Other Liabilities, Noncurrent 667 K USD -27%
Retained Earnings (Accumulated Deficit) -244 M USD +0.71%
Stockholders' Equity Attributable to Parent -1.76 M USD +84.1%
Liabilities and Equity 9.36 M USD +12.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.54 M USD +49.2%
Net Cash Provided by (Used in) Financing Activities 1.87 M USD
Net Cash Provided by (Used in) Investing Activities -17 K USD -100%
Common Stock, Shares Authorized 60 M shares +50%
Common Stock, Shares, Issued 2.66 M shares -88.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -673 K USD +93.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.96 M USD +19.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.49 M USD +1987%
Deferred Tax Assets, Valuation Allowance 69.3 M USD +2.82%
Deferred Tax Assets, Gross 69.5 M USD +2.74%
Operating Lease, Liability 968 K USD -17.1%
Payments to Acquire Property, Plant, and Equipment 17 K USD -64.6%
Lessee, Operating Lease, Liability, to be Paid 1.17 M USD -21.5%
Property, Plant and Equipment, Gross 243 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 349 K USD +4.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 334 K USD +4.38%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 203 K USD -37.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 365 K USD +4.59%
Deferred Tax Assets, Operating Loss Carryforwards 50.1 M USD -1.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 10.6 M USD +5.27%
Lessee, Operating Lease, Liability, to be Paid, Year Four 123 K USD -66.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4 K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.87 M USD -5.51%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%